SG11201901815WA - Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit - Google Patents

Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit

Info

Publication number
SG11201901815WA
SG11201901815WA SG11201901815WA SG11201901815WA SG11201901815WA SG 11201901815W A SG11201901815W A SG 11201901815WA SG 11201901815W A SG11201901815W A SG 11201901815WA SG 11201901815W A SG11201901815W A SG 11201901815WA SG 11201901815W A SG11201901815W A SG 11201901815WA
Authority
SG
Singapore
Prior art keywords
tumor
kit
agent
effect enhancer
salt
Prior art date
Application number
SG11201901815WA
Inventor
Yoshihide Iwaki
Tsukasa KITAHASHI
Shinji Mima
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of SG11201901815WA publication Critical patent/SG11201901815WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

An object of the present invention is to provide an anti-tumor agent and an anti-tumor kit which have superior anti-tumor effect as compared with a therapy with gemcitabine, paclitaxel or a combination thereof as well as an anti-tumor effect enhancer. According to the present invention, provided is an anti-tumor agent including paclitaxel or a salt thereof and 1-(2-deoxy-2-fluoro-4-thio-(3-D-arabinofuranosyl)cytosine or a salt or prodrug thereof
SG11201901815WA 2016-08-31 2017-08-30 Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit SG11201901815WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016169167 2016-08-31
PCT/JP2017/031074 WO2018043530A1 (en) 2016-08-31 2017-08-30 Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit

Publications (1)

Publication Number Publication Date
SG11201901815WA true SG11201901815WA (en) 2019-04-29

Family

ID=61301073

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901815WA SG11201901815WA (en) 2016-08-31 2017-08-30 Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit

Country Status (14)

Country Link
US (1) US11369625B2 (en)
EP (1) EP3508205B1 (en)
JP (2) JP7008025B2 (en)
KR (1) KR102198656B1 (en)
CN (1) CN109641009B (en)
AU (1) AU2017319260B2 (en)
BR (1) BR112019003946A2 (en)
CA (1) CA3035334C (en)
MX (1) MX2019002430A (en)
RU (1) RU2752172C2 (en)
SG (1) SG11201901815WA (en)
TW (1) TWI787201B (en)
WO (1) WO2018043530A1 (en)
ZA (1) ZA201901563B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
TW202002988A (en) * 2018-03-13 2020-01-16 日商富士軟片股份有限公司 Antitumor agent, antitumor effect potentiator and antitumor kit
WO2019176984A1 (en) * 2018-03-13 2019-09-19 富士フイルム株式会社 Antitumor agent, antitumor effect potentiator and antitumor kit
CN117794548A (en) 2021-07-29 2024-03-29 富士胶片株式会社 Pharmaceutical composition and antitumor agent for tumors with reduced function of at least one of BAP 1and PBRM1

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3243425A (en) 1962-10-29 1966-03-29 Purdue Research Foundation Novel sulfur-containing compounds
JPS53119810A (en) 1977-03-25 1978-10-19 Mitsubishi Chem Ind Ltd Preparation of aldehyde chloride
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4220774A (en) 1978-10-26 1980-09-02 Omnium Chimique Vincadifformine synthesis process
JPS5692239A (en) 1979-12-27 1981-07-25 Sagami Chem Res Center Preparation of 5-oxohexyl compound
US4803272A (en) 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
IE74701B1 (en) 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
SE9003151D0 (en) 1990-10-02 1990-10-02 Medivir Ab NUCLEOSIDE DERIVATIVES
JP3138834B2 (en) 1991-12-26 2001-02-26 生化学工業株式会社 Method for producing fucopyranose analog and intermediate compound thereof
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
WO1996001834A1 (en) 1994-07-12 1996-01-25 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted methylidene)-4'-thionucleoside
JPH0853490A (en) 1994-08-09 1996-02-27 Yamasa Shoyu Co Ltd 2'-deoxy-2',2'-dihalogeno-4'-thionucleoside
JP4202327B2 (en) 1996-04-09 2008-12-24 ヤマサ醤油株式会社 1- (2-Deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl) cytosine
US6103707A (en) 1996-04-09 2000-08-15 Yamasa Corporation 9-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)purine derivatives
JP3657008B2 (en) * 1996-04-09 2005-06-08 ヤマサ醤油株式会社 1- (2-Deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl) cytosine
HUP9601756A3 (en) 1996-06-25 1999-05-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical compositions containing them
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP4087471B2 (en) 1997-03-31 2008-05-21 大日本印刷株式会社 Measuring chip for surface plasmon resonance biosensor and manufacturing method thereof
HUP9702348A3 (en) 1997-12-04 2000-12-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical conew anticoagulant glycosides and pharmaceutical compositions containing them mpositions containing them
WO1999043690A1 (en) 1998-02-25 1999-09-02 Rational Drug Design Laboratories L-4'-arabinofuranonucleoside compound and medicine composition comprising the same
CA2338415C (en) 1998-07-23 2006-10-10 Southern Research Institute Preparation of thioarabinofuranosyl compounds and use thereof
AU2001240098A1 (en) 2000-03-08 2001-09-17 Southern Research Institute 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
KR100426030B1 (en) 2000-07-22 2004-04-03 (주) 한켐 Chirality conversion method in lactone sugar compounds
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
EE200300429A (en) 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Use of Tegafur, uracil, folinic acid, paclitaxel and carboplatin in the preparation of a pharmaceutical composition for the treatment of a tumor
US6949522B2 (en) 2001-06-22 2005-09-27 Pharmasset, Inc. β-2′- or 3′-halonucleosides
JP2003172990A (en) 2001-08-03 2003-06-20 Fuji Photo Film Co Ltd Silver halide emulsion and silver halide photographic sensitive material
MXPA04004882A (en) * 2001-11-23 2005-04-11 Chugai Pharmaceutical Co Ltd Method for identification of tumor targeting enzymes.
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003200960B2 (en) 2002-09-18 2005-01-06 Mackinnon, Sebastian Mr System for Ordering, Tracking and Payment of Goods and Services
DE602004014485D1 (en) * 2003-04-07 2008-07-31 Prospect Therapeutics Inc COMPOSITION AND APPLICATIONS OF GALECTIN ANTAGONISTS
US7312228B2 (en) 2003-05-12 2007-12-25 Purdue Research Foundation Cytotoxic indeno and isoindoloisoquinolones
WO2004106280A1 (en) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSR ANTAGONIST
WO2004106352A1 (en) 2003-05-29 2004-12-09 Taisho Pharmaceutical Co., Ltd. Process for producing aldohexopyranose intermediate
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1677822B1 (en) 2003-09-18 2014-04-23 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
PL1853250T3 (en) 2005-02-18 2012-03-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5317257B2 (en) 2005-02-21 2013-10-16 塩野義製薬株式会社 Bicyclic carbamoylpyridone derivatives having HIV integrase inhibitory activity
JP2006335737A (en) 2005-06-03 2006-12-14 Ihara Nikkei Kagaku Kogyo Kk METHOD FOR PRODUCING BENZO[c]HETEROCYCLIC 5-MEMBERED RING COMPOUND
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
WO2007068113A1 (en) 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CN100513395C (en) 2006-04-17 2009-07-15 中国科学院化学研究所 Method of preparing polyhydroxy annular nitrone
ES2600792T3 (en) 2006-05-03 2017-02-10 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of phosphonates, nucleoside phosphonates and antiviral or antiproliferative nucleoside phosphates
CN101200463B (en) 2007-12-11 2011-06-22 复旦大学 Full acylated-4-sulfo-D-ribose and method for making same
AU2008335469A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
US8859589B2 (en) 2008-03-12 2014-10-14 Southern Research Institute Use of 4′-thio-2′-deoxynucleosides as anti orthopoxvirus agents
CN101880287B (en) 2009-05-05 2012-07-25 上海医药工业研究院 Intermediate compounds for thiophane nucleoside analogues and preparation method thereof
KR101814549B1 (en) 2009-12-18 2018-01-04 가부시키가이샤 리브라메디시나 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CN102166190B (en) 2011-04-14 2013-04-10 上海市肺科医院 Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes
TWI594986B (en) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
JP5776564B2 (en) 2012-01-20 2015-09-09 日本精工株式会社 Work processing apparatus and work processing method
CN104203969B (en) 2012-03-28 2016-08-31 富士胶片株式会社 The salt of 1-(2-deoxidation-2-fluoro-4-sulfur generation-β-D-arabinofuranosidase glycosyl) cytosine
SI2833905T1 (en) * 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US20140029864A1 (en) 2012-07-30 2014-01-30 Dror Reif Compression encoding and decoding method and apparatus
SG10201701063WA (en) 2012-08-10 2017-04-27 Taiho Pharmaceutical Co Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
EP3184112B1 (en) 2012-08-13 2020-12-23 FUJIFILM Corporation SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE
TW201542581A (en) 2013-09-11 2015-11-16 Univ Emory Nucleotide and nucleoside therapeutic compositions and uses related thereto
CN106061959B (en) 2014-02-18 2018-11-09 富士胶片株式会社 The manufacturing method and thiophane matrix type sugar compounds of thiophane matrix type sugar compounds
JP6204223B2 (en) 2014-02-19 2017-09-27 富士フイルム株式会社 Method for producing thiopyranose compound, etc.
TWI678373B (en) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 Thionucleoside derivative or its salt and pharmaceutical composition
AU2016240117C1 (en) 2015-04-03 2020-11-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy
JP6450356B2 (en) 2016-02-29 2019-01-09 富士フイルム株式会社 Liquid pharmaceutical formulation
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO2019176984A1 (en) 2018-03-13 2019-09-19 富士フイルム株式会社 Antitumor agent, antitumor effect potentiator and antitumor kit

Also Published As

Publication number Publication date
AU2017319260B2 (en) 2020-01-30
JP2021014474A (en) 2021-02-12
AU2017319260A1 (en) 2019-03-21
CA3035334A1 (en) 2018-03-08
TW201811323A (en) 2018-04-01
KR102198656B1 (en) 2021-01-05
BR112019003946A2 (en) 2019-05-21
NZ751051A (en) 2021-09-24
EP3508205B1 (en) 2022-05-18
ZA201901563B (en) 2020-09-30
WO2018043530A1 (en) 2018-03-08
EP3508205A4 (en) 2019-09-04
CA3035334C (en) 2022-05-10
CN109641009A (en) 2019-04-16
JP7008025B2 (en) 2022-01-25
US20190192546A1 (en) 2019-06-27
CN109641009B (en) 2021-12-31
RU2019105574A (en) 2020-10-01
JPWO2018043530A1 (en) 2019-07-04
EP3508205A1 (en) 2019-07-10
TWI787201B (en) 2022-12-21
KR20190034310A (en) 2019-04-01
MX2019002430A (en) 2019-07-04
RU2019105574A3 (en) 2020-10-01
US11369625B2 (en) 2022-06-28
RU2752172C2 (en) 2021-07-23

Similar Documents

Publication Publication Date Title
MX2023005804A (en) Pyridazinones as parp7 inhibitors.
UA117976C2 (en) Aminopyrimidinyl compounds as jak inhibitors
EA201791563A1 (en) SUBSTITUTED NUCLEOSIDE DERIVATIVES, USEFUL AS AN AGENT AGAINST CANCER
EA201891200A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2020004504A (en) Phenoxymethyl derivatives.
PH12017502363A1 (en) Brk inhibitory compound
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201901815WA (en) Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
JO3155B1 (en) Sweet flavor modifier
EA201792021A1 (en) JAK INHIBITOR
MX2020006237A (en) Compounds for treatment of diseases related to dux4 expression.
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2018001576A (en) Pyridines and their use in the treatment of cancer.
MX2017013360A (en) Methods for treating cancer.
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EA201791530A1 (en) NEW N-ACYLARYL SULPHONAMIDE DERIVATIVES AS AN INHIBITORS AMINOACYL-tRNA SYNTHETASIS
MY193239A (en) Novel b-lactamase inhibitors
MX2018008307A (en) Ascochlorin derivative and use thereof as ampk activator.
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
EA201791099A1 (en) QUINOLIN CARBOXAMIDE FOR USE IN THE TREATMENT OF LEUKEMIA
MX2019008375A (en) Thiobenzoimidazole as fungicides.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2018002611A (en) Antitumor agent for biliary cancer and treatment method of biliary cancer.